Concord Biotech (NSE:CONCORDBIO, BOM:543960) said the European Union Good Manufacturing Practice (EU GMP) inspection at its active pharmaceutical ingredient manufacturing facility at Dholka in Gujarat, India, has been completed.
The inspection was conducted from July 14 to July 18, as per a filing made on Friday with the Indian bourses.
The company's shares were down over 1% in recent trade.